Cited by 347Genetics and Neurodevelopmental DisordersAutism Spectrum Disorder ResearchEpigenetics and DNA Methylation

Reduced meCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation

Open access
Nagarajan, Raman, Hogart, Amber, Gwye, Ynnez, Martin, Michelle R, LaSalle, Janine M.·2006·Epigenetics

Abstract

Mutations in MECP2, encoding methyl CpG binding protein 2 (MeCP2), cause most cases of Rett syndrome (RTT), an X-linked neurodevelopmental disorder. Both RTT and autism are "pervasive developmental disorders" and share a loss of social, cognitive and language skills and a gain in repetitive stereotyped behavior, following apparently normal perinatal development. Although MECP2 coding mutations are a rare cause of autism, MeCP2 expression defects were previously found in autism brain. To further study the role of MeCP2 in autism spectrum disorders (ASDs), we determined the frequency of MeCP2 expression defects in brain samples from autism and other ASDs. We also tested the hypotheses that MECP2 promoter mutations or aberrant promoter methylation correlate with reduced expression in cases of idiopathic autism. MeCP2 immunofluorescence in autism and other neurodevelopmental disorders was quantified by laser scanning cytometry and compared with control postmortem cerebral cortex samples on a large tissue microarray. A significant reduction in MeCP2 expression compared to age-matched controls was found in 11/14 autism (79%), 9/9 RTT (100%), 4/4 Angelman syndrome (100%), 3/4 Prader-Willi syndrome (75%), 3/5 Down syndrome (60%), and 2/2 attention deficit hyperactivity disorder (100%) frontal cortex samples. One autism female was heterozygous for a rare MECP2 promoter variant that correlated with reduced MeCP2 expression. A more frequent occurrence was significantly increased MECP2 promoter methylation in autism male frontal cortex compared to controls. Furthermore, percent promoter methylation of MECP2 significantly correlated with reduced MeCP2 protein expression. These results suggest that both genetic and epigenetic defects lead to reduced MeCP2 expression and may be important in the complex etiology of autism.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/epi.1.4.3514

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In ASD, global methylation differences are observed in neuronal development genes.

    “In ASD, global methylation differences are observed in neuronal development genes”

    From The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry (2025) · cites this paper as [18]

    The Epigenetic Alteration of MECP2 in Autism section (e7) reports increased methylation of the MECP2 promoter in autism frontal-cortex samples compared with controls. This supports an ASD-associated methylation difference, but the study examines a specific gene promoter, not global methylation differences across neuronal-development genes. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • In MECP2, both mutations and methylation abnormalities interact to disrupt synaptic development.

    “In MECP2, both mutations and methylation abnormalities interact to disrupt synaptic development”

    From The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry (2025) · cites this paper as [18]

    The paper discusses MECP2 mutations in its introductory material and reports increased MECP2 promoter methylation correlated with reduced MeCP2 expression in autism frontal cortex (Epigenetic Alteration of MECP2 in Autism, e7). It does not show that mutations and methylation abnormalities interact, or that their interaction disrupts synaptic development. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Some transcription factors that lack a methyl-CpG binding domain can interact with methylated DNA.

    “evidence is emerging to suggest that transcription factors lacking a MBD can also interact with methylated DNA”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Amir RE, Van den Veyver IB, Schultz R, Malicki DM, Tran CQ, Dahle EJ, Philippi A, Timar L, Percy AK, Motil KJ, et al. Influence of mutation type and X chromosome inactiva- tion on Rett syndrome phenotypes. Ann Neurol 2000; 47:670-9.
  2. Kosaki K, McGinniss MJ, Veraksa AN, McGinnis WJ, Jones KL. Prader-Willi and Angelman syndromes: diagnosis with a bisulfite-treated methylation-specific PCR method. Am J Med Genet 1997; 73:308-13.

Cited by

Sorted by citations

Authors
Nagarajan, R., Hogart, A., Gwye, Y., Martin, M. R., & LaSalle, J. M.
Affiliations
University of California, Davis (US)
Venue
Epigenetics
Published
2006-10-23
Volume
1
Issue
4
Pages
172-182
ISSN
  • 1559-2294 (ISSN-L)
  • 1559-2308
OpenAlex
W2149522457
Cited by
347
References
56
Citations by year
2026: 3 · 2025: 9 · 2024: 12 · 2023: 11 · 2022: 19 · 2021: 24 · 2020: 20 · 2019: 17 · 2018: 11 · 2017: 15 · 2016: 23 · 2015: 34 · 2014: 23 · 2013: 28 · 2012: 16
FWCI
7.33
Type
journal article
Language
en
Open access
Locations
  • Epigenetics (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • University of Miami
  • National Institutes of Health
  • National Institute of Mental Health (R24MH068855)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD048799)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords
MeCP2, autism spectrum disorder, Rett syndrome, promoter mutations, frontal cortex, Angelman syndrome, Prader-Willi syndrome, Down syndrome, attention deficit hyperactivity disorder, epigenetic defects, neurodevelopmental disorders, pervasive developmental disorders
MeSH terms
Adolescent, Adult, Amino Acid Sequence, Autistic Disorder, Child, Child, Preschool, Female, Frontal Lobe, Humans, Infant, Male, Middle Aged, Promoter Regions, Genetic, DNA Methylation, Tissue Array Analysis, Methyl-CpG-Binding Protein 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review